COMMUNIQUÉS West-GlobeNewswire

ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

08/04/2019 - 13:00

Data demonstrates that exebacase activates key host factors in human blood to potentiate methicillin-resistant Staphylococcus aureus bacteriolysis YONKERS, N.Y., April 08, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation [...]

Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019

08/04/2019 - 12:50

-- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH resolution on liver biopsy at 36 weeks -- -- The [...]

Exactus Applauds Executive Chairman, Jonathan Gilbert on Launch of Impact Biosciences Corp.

08/04/2019 - 12:30

DELRAY BEACH, Fla., April 08, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB: EXDI) , a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, applauds its Executive Chairman of the Board, [...]

XOMA Acquires Royalty Rights to Five Hematology Candidates

08/04/2019 - 12:00

EMERYVILLE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has agreed to acquire the rights to potential royalty payments and a portion of the potential milestone payments [...]

Arrayit Corporation Announces Allergy Testing Services Evaluation Expansion by a Major Pharmacy Retailer

08/04/2019 - 11:30

Sunnyvale, April 08, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, announces that its proprietary finger stick allergy testing services continue to be [...]

ViroGates notice to convene the annual general meeting on 25 April 2019

08/04/2019 - 11:17

We hereby convene the annual general meeting of ViroGates A/S on 25 April 2019 at 5:00 pm at Comwell Holte, Kongevejen 495A, DK-2840 Holte. The agenda and full proposals can be read in the attached document. For further [...]

TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy

08/04/2019 - 11:00

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 08, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of [...]

PCI Biotech: Final confirmation of successful safety read-out in the Phase I Extension study

08/04/2019 - 10:32

Oslo (Norway), 8 April 2019 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced final confirmation of [...]

CLS Releases White Paper Regarding its imILT® Immuno-Stimulating Method for Treating Cancer Tumours at ECIO 2019 Conference

08/04/2019 - 09:45

Technical White Paper Also Available Via the Company’s Website LUND, Sweden, April 08, 2019 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) today released a technical white paper regarding the company’ [...]

GN Store Nord A/S issues options to the executive management and key employees

08/04/2019 - 08:50

In accordance with section 3.3.10 of the Nasdaq Copenhagen Rules for Issuers of Shares and with reference to the Remuneration Policy, including General Guidelines for Incentive Pay approved at the annual general meeting [...]

Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance

08/04/2019 - 07:59

Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance Paris – April 8, 2019 – Sanofi and Alnylam have agreed to conclude the research and option phase of the companies’ 2014 RNAi [...]

Genkyotex to Present Updated Interim Results From Phase 2 Trial of GKT831 in Primary Biliary Cholongitis at 2019 EASL International Liver Congress (ILC)

08/04/2019 - 07:00

Interim results selected for oral presentation and inclusion in “Best of ILC” summary All patients have completed treatment; favorable safety profile with no drop outs or treatment interruptions due to pruritus Final [...]

Genkyotex présente les résultats intermédiaires de son étude de phase 2 avec le GKT831 dans la cholangite biliaire primitive lors de l’International Liver Congress (EASL) 2019

08/04/2019 - 07:00

Résultats intermédiaires retenus pour présentation orale et sélectionnés parmi les meilleurs résumés « Best of ILC ». Tous les patients ont terminé le traitement ; profil de sécurité de GKT831 favorable, aucun abandon [...]

Quinton C. Oswald Explains His Biggest Business Growth Strategy

08/04/2019 - 06:00

Vero Beach, Florida, April 08, 2019 (GLOBE NEWSWIRE) -- After years of success in big Pharma and biotech field, Quinton C. Oswald recently took time to look back at his entire career and identify the main tip that [...]

Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

08/04/2019 - 01:15

Consistent, Marked, and Sustained Lowering of Elevated Plasma Arginine with Pegzilarginase Clinically Impactful Responses Captured by Mobility and Adaptive Behavior Assessments Management to Host Conference Call at 8:30 [...]

RavenQuest Secures Health Canada Cultivation License at Edmonton Facility

05/04/2019 - 23:35

VANCOUVER, British Columbia, April 05, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “ Company ” or “ RavenQuest ”) a federally-licensed producer of cannabis, is pleased to [...]

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05/04/2019 - 22:30

BURLINGTON, Mass., April 05, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 61,000 stock options and 26,900 [...]

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05/04/2019 - 22:30

WALTHAM Mass. and CRESTWOOD, Ky., April 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]

Codexis Senior Vice President of R&D Dr. Jim Lalonde Announces Plan to Resign

05/04/2019 - 22:05

REDWOOD CITY, Calif., April 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that Jim Lalonde, Ph.D., Senior Vice President of Research and Development, will [...]